Andrew Tsai

Corinne Jenkins

Jason Butler

Paul Matteis

- Athira Pharma, Inc. will effect a **10-for-1** reverse stock split of its common stock.  **[1620463_0000950170-25-114093_atha-ex99_1.htm:0]** **[1620463_0000950170-25-114093_atha-20250910.htm:1]** 
- The reverse stock split will become effective on **September 17, 2025, at 5:00 p.m., Eastern Time**, with trading on a split-adjusted basis expected to begin on Nasdaq on **September 18, 2025**.  **[1620463_0000950170-25-114093_atha-ex99_1.htm:0]** **[1620463_0000950170-25-114093_atha-20250910.htm:1]** 
- The primary purpose of the split is to increase the price per share to meet the **$1.00 minimum bid price requirement** for continued Nasdaq listing.  **[1620463_0000950170-25-114093_atha-ex99_1.htm:0]** 
- As a result of the split, the total number of authorized common shares will be reduced from **900,000,000 to 90,000,000**, and any fractional shares will be paid out in cash.  **[1620463_0000950170-25-114093_atha-ex99_1.htm:0]** **[1620463_0000950170-25-114093_atha-20250910.htm:1]**

Athira Pharma Announces Reverse Stock Split

- Athira Pharma, Inc. (NASDAQ: ATHA) announced a **10-for-1 reverse stock split**.  **[1620463_1cdcf9ad85764b0ea8f5e112db57aaa9_0]** 
- The reverse stock split will become effective on **September 17, 2025**, with split-adjusted trading expected to begin on **September 18, 2025** under the existing ticker symbol "ATHA".  **[1620463_1cdcf9ad85764b0ea8f5e112db57aaa9_0]** 
- The primary goal of the split is to **increase the price per share** to meet the **$1.00 minimum bid price requirement for continued listing on Nasdaq**.  **[1620463_1cdcf9ad85764b0ea8f5e112db57aaa9_0]** 
- This action will combine **ten (10) shares of common stock into one**, and the total authorized common shares will be reduced from 900,000,000 to **90,000,000**.  **[1620463_1cdcf9ad85764b0ea8f5e112db57aaa9_0]**

Athira Pharma (ATHA)